FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2161289703> ?p ?o ?g. }

• W2161289703 endingPage "747" @default.
• W2161289703 startingPage "741" @default.
• W2161289703 abstract "Purpose To evaluate the efficacy and toxicity of concurrent chemoradiotherapy (CCRT) with curative intent in patients with stage IVB cervical cancer initially presenting with paraortic and left supraclavicular lymph node metastases. Methods and Materials The medical records of 25 patients with both paraortic and left supraclavicular lymph nodal metastases (group I) were reviewed and compared with those of 101 women with paraortic lymph node metastases alone (group II). Group I received a mean 59.4 Gy to the paraortic and left supraclavicular areas and 50.4 Gy to the pelvis, followed by 30 Gy of high-dose-rate brachytherapy in 6 fractions. Group II received the same dose to the paraortic area and pelvis followed by intracavitary brachytherapy. All patients received platinum-based chemotherapy simultaneously. Results Of the 25 patients in group I, 16 (64%) experienced acute grade 3-4 hematologic toxicities, and 1 had a late grade 3 genitourinary toxicity. Complete responses, including the primary mass and pelvic, paraortic, and left supraclavicular lymph nodes, were observed in 13 patients (52%). At a median follow-up of 32 months for surviving patients, 3 experienced in-field failure, 6 showed distant failure, and 9 showed both. The 3-year overall and disease-free survival rates were 49% and 33%, respectively. In comparison, of the 101 patients in group II, 16 showed in-field failure, 14 experienced distant failure, and 11 showed both. The 3-year overall and disease-free survival rates were 69% and 57%, respectively. Conclusions Curative CCRT is feasible in patients with stage IVB cervical cancer presenting with paraortic and left supraclavicular lymph nodal metastases, with acceptable late toxicity and high response rates, despite high rates of acute hematologic toxicity. To evaluate the efficacy and toxicity of concurrent chemoradiotherapy (CCRT) with curative intent in patients with stage IVB cervical cancer initially presenting with paraortic and left supraclavicular lymph node metastases. The medical records of 25 patients with both paraortic and left supraclavicular lymph nodal metastases (group I) were reviewed and compared with those of 101 women with paraortic lymph node metastases alone (group II). Group I received a mean 59.4 Gy to the paraortic and left supraclavicular areas and 50.4 Gy to the pelvis, followed by 30 Gy of high-dose-rate brachytherapy in 6 fractions. Group II received the same dose to the paraortic area and pelvis followed by intracavitary brachytherapy. All patients received platinum-based chemotherapy simultaneously. Of the 25 patients in group I, 16 (64%) experienced acute grade 3-4 hematologic toxicities, and 1 had a late grade 3 genitourinary toxicity. Complete responses, including the primary mass and pelvic, paraortic, and left supraclavicular lymph nodes, were observed in 13 patients (52%). At a median follow-up of 32 months for surviving patients, 3 experienced in-field failure, 6 showed distant failure, and 9 showed both. The 3-year overall and disease-free survival rates were 49% and 33%, respectively. In comparison, of the 101 patients in group II, 16 showed in-field failure, 14 experienced distant failure, and 11 showed both. The 3-year overall and disease-free survival rates were 69% and 57%, respectively. Curative CCRT is feasible in patients with stage IVB cervical cancer presenting with paraortic and left supraclavicular lymph nodal metastases, with acceptable late toxicity and high response rates, despite high rates of acute hematologic toxicity." @default.
• W2161289703 created "2016-06-24" @default.
• W2161289703 creator A5024811015 @default.
• W2161289703 creator A5029846673 @default.
• W2161289703 creator A5034484816 @default.
• W2161289703 creator A5078809545 @default.
• W2161289703 creator A5080746544 @default.
• W2161289703 creator A5083728536 @default.
• W2161289703 date "2012-11-01" @default.
• W2161289703 modified "2023-10-18" @default.
• W2161289703 title "Curative Chemoradiotherapy in Patients With Stage IVB Cervical Cancer Presenting With Paraortic and Left Supraclavicular Lymph Node Metastases" @default.
• W2161289703 cites W1755258021 @default.
• W2161289703 cites W1971494165 @default.
• W2161289703 cites W2001965256 @default.
• W2161289703 cites W2014368499 @default.
• W2161289703 cites W2080309100 @default.
• W2161289703 cites W2084250890 @default.
• W2161289703 cites W2104360894 @default.
• W2161289703 cites W2110057444 @default.
• W2161289703 cites W2118508302 @default.
• W2161289703 cites W2126768246 @default.
• W2161289703 cites W2150068929 @default.
• W2161289703 cites W2150611525 @default.
• W2161289703 cites W2153535910 @default.
• W2161289703 cites W3203488151 @default.
• W2161289703 cites W4231096603 @default.
• W2161289703 cites W4240340450 @default.
• W2161289703 doi "https://doi.org/10.1016/j.ijrobp.2012.01.070" @default.
• W2161289703 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22898382" @default.
• W2161289703 hasPublicationYear "2012" @default.
• W2161289703 type Work @default.
• W2161289703 sameAs 2161289703 @default.
• W2161289703 citedByCount "49" @default.
• W2161289703 countsByYear W21612897032013 @default.
• W2161289703 countsByYear W21612897032015 @default.
• W2161289703 countsByYear W21612897032016 @default.
• W2161289703 countsByYear W21612897032017 @default.
• W2161289703 countsByYear W21612897032018 @default.
• W2161289703 countsByYear W21612897032019 @default.
• W2161289703 countsByYear W21612897032020 @default.
• W2161289703 countsByYear W21612897032021 @default.
• W2161289703 countsByYear W21612897032022 @default.
• W2161289703 countsByYear W21612897032023 @default.
• W2161289703 crossrefType "journal-article" @default.
• W2161289703 hasAuthorship W2161289703A5024811015 @default.
• W2161289703 hasAuthorship W2161289703A5029846673 @default.
• W2161289703 hasAuthorship W2161289703A5034484816 @default.
• W2161289703 hasAuthorship W2161289703A5078809545 @default.
• W2161289703 hasAuthorship W2161289703A5080746544 @default.
• W2161289703 hasAuthorship W2161289703A5083728536 @default.
• W2161289703 hasConcept C121608353 @default.
• W2161289703 hasConcept C126322002 @default.
• W2161289703 hasConcept C126838900 @default.
• W2161289703 hasConcept C133507102 @default.
• W2161289703 hasConcept C141071460 @default.
• W2161289703 hasConcept C146357865 @default.
• W2161289703 hasConcept C151730666 @default.
• W2161289703 hasConcept C2777416452 @default.
• W2161289703 hasConcept C2778220009 @default.
• W2161289703 hasConcept C2778357063 @default.
• W2161289703 hasConcept C2778424827 @default.
• W2161289703 hasConcept C2779013556 @default.
• W2161289703 hasConcept C2779223589 @default.
• W2161289703 hasConcept C2780849966 @default.
• W2161289703 hasConcept C509974204 @default.
• W2161289703 hasConcept C71924100 @default.
• W2161289703 hasConcept C86803240 @default.
• W2161289703 hasConceptScore W2161289703C121608353 @default.
• W2161289703 hasConceptScore W2161289703C126322002 @default.
• W2161289703 hasConceptScore W2161289703C126838900 @default.
• W2161289703 hasConceptScore W2161289703C133507102 @default.
• W2161289703 hasConceptScore W2161289703C141071460 @default.
• W2161289703 hasConceptScore W2161289703C146357865 @default.
• W2161289703 hasConceptScore W2161289703C151730666 @default.
• W2161289703 hasConceptScore W2161289703C2777416452 @default.
• W2161289703 hasConceptScore W2161289703C2778220009 @default.
• W2161289703 hasConceptScore W2161289703C2778357063 @default.
• W2161289703 hasConceptScore W2161289703C2778424827 @default.
• W2161289703 hasConceptScore W2161289703C2779013556 @default.
• W2161289703 hasConceptScore W2161289703C2779223589 @default.
• W2161289703 hasConceptScore W2161289703C2780849966 @default.
• W2161289703 hasConceptScore W2161289703C509974204 @default.
• W2161289703 hasConceptScore W2161289703C71924100 @default.
• W2161289703 hasConceptScore W2161289703C86803240 @default.
• W2161289703 hasIssue "3" @default.
• W2161289703 hasLocation W21612897031 @default.
• W2161289703 hasLocation W21612897032 @default.
• W2161289703 hasOpenAccess W2161289703 @default.
• W2161289703 hasPrimaryLocation W21612897031 @default.
• W2161289703 hasRelatedWork W2376116016 @default.
• W2161289703 hasRelatedWork W2384708512 @default.
• W2161289703 hasRelatedWork W2404243584 @default.
• W2161289703 hasRelatedWork W2409536117 @default.
• W2161289703 hasRelatedWork W2468611194 @default.
• W2161289703 hasRelatedWork W2966036943 @default.
• W2161289703 hasRelatedWork W3029595631 @default.
• W2161289703 hasRelatedWork W3104537559 @default.
• W2161289703 hasRelatedWork W4206581437 @default.

• next